# A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

> **NCT02217007** · PHASE2 · WITHDRAWN · sponsor: **Synchroneuron Inc.**

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** SNC-102 sustained release tablet

## Key facts

- **NCT ID:** NCT02217007
- **Lead sponsor:** Synchroneuron Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding stopped, company closed
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02217007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02217007, "A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02217007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*